The use of ciclosporin in psoriasis.
Ciclosporin is a cyclic undecapeptide discovered in the 1970s to possess a potent inhibitory action on T lymphocytes. The subsequent discovery, in 1979, that it was remarkably effective in treatment of psoriasis transformed thinking about the nature of the disease, which subsequently became generally recognized as autoimmune in nature. Ciclosporin remains one of the most effective and rapidly acting treatments currently available for psoriasis. Virtually all the diverse manifestations of this disease can respond. The main side effects are nephrotoxicity and hypertension. There is considerable variation between individuals in susceptibility to these so careful monitoring is required. Ciclosporin should be used in single or intermittent short courses for all except the most severe cases as this is safer than continuous treatment. The rate of improvement depends very much on the dose, which ranges from 2 to 5.0 mg/kg/day. Ciclosporin can be combined with any topical treatment and a useful dose-sparing effect can be achieved in this way if patients are compliant. In severe cases ciclosporin is often used in combination with other systemic antipsoriatic drugs in order to spare the dose of each agent and reduce toxicity. Concurrent or intercurrent use of ultraviolet therapy is discouraged due to the increased risk of non-melanoma skin cancer. This article reviews the mode of action, pharmacokinetics, indications, contraindications, side effects, dosage regimens, pretreatment screening and monitoring, drug interactions, and use of treatment combinations with ciclosporin in the management of psoriasis.
Berth-Jones
John
J
Department of Dermatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
D000328:Adult; D002648:Child; D016572:Cyclosporine / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011565:Psoriasis / Q000188:drug therapy*
D003879:Dermatologic Agents; D016572:Cyclosporine